How controlling fat 'doormen' could lead to new obesity treatments

Obesity
Targeting the enzyme O-GlcNAc transferase with drugs may offer a new way to combat obesity, Yale researchers say. (Creative Commons CC0)

In healthy people, fat cells take in nutrients and let out energy-supplying lipids in a finely tuned process that prevents the excessive buildup of belly fat. When this process goes wrong, however, obesity can emerge.

Scientists at Yale University have discovered a new regulator of fat transport—an enzyme they believe could be targeted with drugs to help control obesity. They described the discovery in the journal Nature Communications.

The enzyme is called O-GlcNAc transferase (OGT), and its role in maintaining a healthy metabolism has been widely reported. In 2015, for example, a Johns Hopkins University team discovered that high levels of OGT disrupt energy production in a way that leads to high blood sugar.

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

The new study from Yale focuses on OGT’s impact on “fat droplet sentinels,” which are molecules inside of fat cells that act like “doormen” for nutrients and fat, according to a statement from the university. The researchers discovered mice that lack the enzyme are lean and their cells burn off lipids at a faster rate than they take in carbohydrates. Mice that overexpress OGT, by contrast, take in more carbohydrates, they reported.

"The commander of this doorman makes it easier for nutrients to get in, but harder for lipids to get out," said senior author Xiaoyong Yang, Ph.D., associate professor of comparative medicine and of cellular and molecular physiology at Yale's medical school, in a statement.

RELATED: Hibernating animals offer genetic clues to obesity, metabolic diseases

Yale has undertaken a variety of research efforts aimed at reducing the buildup of unhealthy fat in the body. In 2018, a team at the Yale Cardiovascular Research Center published a mouse study that showed that inhibiting the VEGF-A receptor FLT1 normalized fat transport in the body and prevented weight gain.

As for OGT overexpression, it doesn’t just control the flow of nutrients and fats. It also sends signals to the brain that trigger overeating, Yang’s team previously discovered. "This makes OGT a very attractive target to pharmaceutically treat obesity," he said.

Suggested Articles

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.

Daiichi Sankyo has penned a deal with Syneos Health to launch a “coalition” that sees the CRO work on its big-name antibody-drug conjugate targets.

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.